CR20130499A - Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) - Google Patents
Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)Info
- Publication number
- CR20130499A CR20130499A CR20130499A CR20130499A CR20130499A CR 20130499 A CR20130499 A CR 20130499A CR 20130499 A CR20130499 A CR 20130499A CR 20130499 A CR20130499 A CR 20130499A CR 20130499 A CR20130499 A CR 20130499A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tfpi
- monoclonal antibodies
- inhibitor
- antibodies against
- tissular
- Prior art date
Links
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title abstract 2
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20130499A true CR20130499A (es) | 2013-10-24 |
Family
ID=46932389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20130499A CR20130499A (es) | 2011-04-01 | 2013-09-30 | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) |
Country Status (37)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792032B1 (ko) | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| BRPI0924058B1 (pt) † | 2008-12-22 | 2021-08-17 | Novo Nordisk A/S | Anticorpos monoclonais, seus usos, bem como composição farmacêutica |
| ES2765418T3 (es) | 2010-03-01 | 2020-06-09 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI) |
| CA2793465C (en) | 2010-03-19 | 2022-06-14 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| MY190951A (en) * | 2011-04-01 | 2022-05-24 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2013141965A1 (en) * | 2012-03-21 | 2013-09-26 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| CA2868789A1 (en) * | 2012-03-30 | 2013-10-03 | Bayer Healthcare Llc | Protease-regulated antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| CN105209497B (zh) * | 2013-03-15 | 2021-09-07 | 诺和诺德股份有限公司 | 能够特异性结合组织因子途径抑制物上的两个表位的抗体 |
| ES2657304T3 (es) | 2013-03-15 | 2018-03-02 | Bayer Healthcare Llc | Variantes de anticuerpo anti TFPI con unión diferencial a lo largo del intervalo de pH para mejorar la farmacocinética |
| WO2015007880A1 (en) * | 2013-07-19 | 2015-01-22 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| US11279771B2 (en) * | 2014-09-17 | 2022-03-22 | Novo Nordisk A/S | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
| AU2015384281B2 (en) * | 2015-02-25 | 2018-11-22 | Mogam Institute For Biomedical Research | Novel antibody binding to TFPI and composition comprising the same |
| KR20230074843A (ko) | 2015-08-19 | 2023-05-31 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
| WO2020021890A1 (ja) * | 2018-07-25 | 2020-01-30 | ソニー株式会社 | 血液凝固系解析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| BRPI0924058B1 (pt) * | 2008-12-22 | 2021-08-17 | Novo Nordisk A/S | Anticorpos monoclonais, seus usos, bem como composição farmacêutica |
| ES2765418T3 (es) * | 2010-03-01 | 2020-06-09 | Bayer Healthcare Llc | Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI) |
| MY190951A (en) * | 2011-04-01 | 2022-05-24 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2012
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko not_active Expired - Fee Related
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en not_active Ceased
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Ceased
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20130499A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| CR20120453A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfp) | |
| CY1123145T1 (el) | Anti-cd40 αντισωματα | |
| CR20110066A (es) | Anticuerpos monoclonales contra el factor tisular inhibidor de la via | |
| GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| CL2015002756A1 (es) | Moléculas fc biespecíficas | |
| CR20120577A (es) | Anticuerpos hacia gdf8 humano | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| CO6781491A2 (es) | Anticuerpos del cea | |
| CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
| ECSP14028523A (es) | Moléculas de anticuerpo anti-gcc y uso de las mismas | |
| CO7010784A2 (es) | Moléculas que son anticuerpos con especificidad por ox40 humano | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| MX2024012548A (es) | Metodos y medios para la produccion de moleculas de tipo ig | |
| CU24498B1 (es) | Anticuerpos de factor xi | |
| CO7151530A2 (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| MX2013013832A (es) | Proteínas de unión receptoras fc. | |
| EP2797958A4 (en) | Lightweight, bridged bispecific antibody | |
| UY33850A (es) | Anticuerpos anti ? cd38 | |
| CR20110544A (es) | Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7 | |
| CR20150575A (es) | Anticuerpos humanos pac1 | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων |